The Food and Drug Administration rejected AstraZeneca’s new drug application for ZS-9, a drug the company is developing as a potential treatment for hyperkalemia.
Hyperkalemia is a condition that causes high potassium levels in the bloodstream. It is typically associated with chronic kidney disease. Health officials estimate between 40 to 50 percent of chronic kidney disease patients get hyperkalemia — as compared to 2 percent of the general population. The condition can cause cardiac arrhythmias…
The Food and Drug Administration rejected AstraZeneca’s new drug application for ZS-9, a drug the company is developing as a potential treatment for hyperkalemia.
Hyperkalemia is a condition that causes high potassium levels in the bloodstream. It is typically associated with chronic kidney disease. Health officials estimate between 40 to 50 percent of chronic kidney disease patients get hyperkalemia — as compared to 2 percent of the general population. The condition can cause cardiac arrhythmias…